{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174061","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.345244+00:00","generated_at":"2026-05-17T19:24:31.458093+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prothena partner Novo Nordisk to advance coramitug to Phase 3 for ATTR-CM","bullets":["Novo Nordisk plans Phase 3 program for coramitug in ATTR-CM, start expected in 2025.","Prothena eligible for up to $1.2B in milestones, $100M received to date.","Clinical milestone payment triggered when prespecified enrollment criteria met in Phase 3.","Coramitug is a potential first-in-class amyloid depleter antibody."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174061","json":"https://secwatch.observer/filing/0001193125-25-174061.json","markdown":"https://secwatch.observer/filing/0001193125-25-174061.md","text":"https://secwatch.observer/filing/0001193125-25-174061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000119312525174061/0001193125-25-174061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000119312525174061/d42243d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:24:31.458093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}